

08/8524825

ABSTRACT OF THE DISCLOSURE

The present invention is directed to a molecule comprising a polypeptide having substantial homology with a CTL epitope selected from the group consisting of

5 ADLMGYIPLV (Core<sub>131-140</sub>; SEQ ID NO:1), LLALLSCLTV (Core<sub>178-187</sub>; SEQ ID NO:2), QLRRHIDLLV (SEQ ID NO:55), LLCPAGHAV (NS3<sub>1169-1177</sub>; SEQ ID NO:26), KLVALGINAV (NS3<sub>1406-1415</sub>; SEQ ID NO:28), SLMAFTAAV (NS4<sub>1789-1797</sub>; SEQ ID NO:34), LLFNILGGWV (NS4<sub>1807-1816</sub>;

10 SEQ ID NO:35), and ILDSFDPLV (NS5<sub>2252-2260</sub>; SEQ ID NO:42). Such molecules are used for the treatment and prevention of acute or chronic HCV hepatitis; suitable pharmaceutical compositions and methods using such compositions are disclosed.

08854825-051297